Sensus Launches Sensus Healthcare Financial Services to Facilitate Customer Acquisition of SRT Technology

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the launch of Sensus Healthcare Financial Services, a new program intended to make it easier for dermatology practices to acquire Sensus' superficial radiotherapy (SRT) systems through a streamlined process and flexible financing structure.

Business Wire • Feb 18, 2026

Sensus Healthcare, Inc. (SRTS) Q4 2025 Earnings Call Transcript

Sensus Healthcare, Inc. (SRTS) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 13, 2026

Sensus Healthcare Reports Fourth Quarter 2025 Financial Results Highlighted by Publication of Dedicated CPT Codes for SRT to Treat Non-Melanoma Skin Cancer

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and twelve months ended December 31, 2025. Highlights include the following: Revenues were $4.9 million for the quarter and $27.5 million for the year Net loss was $3.2 million for the quarter and $7.7 milli.

Business Wire • Feb 12, 2026

Sensus Healthcare to Report Fourth Quarter and Full Year 2025 Financial Results and Hold Business Update Conference Call on February 12, 2026

BOCA RATON, Fla.--(BUSINESS WIRE)---- $SRTS--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and ans.

Business Wire • Feb 5, 2026

Sensus Healthcare Appoints Larry Biscotti to its Board of Directors

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Larry Biscotti to its Board of Directors, effective immediately. With this appointment the Sensus Healthcare Board has six Directors, including four independent Directors. Mr. Biscotti brings more than 25 years of.

Business Wire • Jan 7, 2026

Sensus Healthcare to Hold Investor Meetings During JPM Week 2026 in San Francisco

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced that management will be meeting with members of the healthcare investment community January 12–14, 2026, in San Francisco during the 44th Annual J.P. Morgan Healthcare Conference. “With recently established coding by the Centers for.

Business Wire • Jan 7, 2026

Sensus Healthcare Expands Role of President Michael Sardano to Include Chief Commercial Officer

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced that President Michael Sardano has been appointed to the additional role of Chief Commercial Officer. In this newly created position, Mr. Sardano will direct the company's global sales, marketing and commercial strategy across its po.

Business Wire • Nov 14, 2025

Sensus Healthcare Appoints Eric Sachetta to its Board of Directors

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Eric Sachetta to the Company's Board of Directors. Mr. Sachetta is filling the vacancy that resulted from the passing of long-serving Director Bill McCall. Throughout his career, Mr. Sachetta has held a range of le.

Business Wire • Nov 12, 2025

Sensus Healthcare, Inc. (SRTS) Q3 2025 Earnings Call Transcript

Sensus Healthcare, Inc. ( SRTS ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Joseph Sardano - Co-Founder, Chairman & CEO Michael Sardano - President, General Counsel, Corporate Secretary & Director Javier Rampolla - Chief Financial Officer Conference Call Participants Tirth Patel - Lippert/Heilshorn & Associates, Inc. Anthony Vendetti - Maxim Group LLC, Research Division Benjamin Haynor - Lake Street Capital Markets, LLC, Research Division Eduardo Martinez-Montes - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, and welcome to the Sensus Healthcare Third Quarter 2025 Financial Results Conference Call.

Seeking Alpha • Nov 7, 2025

Sensus Healthcare Reports Third Quarter 2025 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and nine months ended September 30, 2025. Highlights of the third quarter of 2025 and subsequent weeks include the following: CMS established coding validating SRT for treating non-melanoma skin cancer Revenu.

Business Wire • Nov 6, 2025